OLMA OLEMA PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, OLEMA PHARMACEUTICALS INC reported revenue of n/a, net income of −$63.2M and diluted EPS of −$0.61; for the fiscal year ended December 2025 revenue was n/a.
OLMA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$179M, net income −$162M (margin n/a), EPS −$1.87
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$142M, net income −$129M (margin n/a), EPS −$2.20
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$105M, net income −$96.7M (margin n/a), EPS −$2.14
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$107M, net income −$105M (margin n/a), EPS −$2.62
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$71.5M, net income −$71.1M (margin n/a), EPS −$1.80
OLMA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$63.2M, EPS −$0.61
- Quarter ended Mar 31, 2026: revenue n/a, net income −$53.1M, EPS −$0.52
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$46.1M, EPS −$0.51
- Quarter ended Sep 30, 2025: revenue n/a, net income −$42.2M, EPS −$0.49
- Quarter ended Jun 30, 2025: revenue n/a, net income −$43.8M, EPS −$0.51
- Quarter ended Mar 31, 2025: revenue n/a, net income −$30.4M, EPS −$0.36
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$33.6M, EPS −$0.50
- Quarter ended Sep 30, 2024: revenue n/a, net income −$34.6M, EPS −$0.60
- Quarter ended Jun 30, 2024: revenue n/a, net income −$30.4M, EPS −$0.54
- Quarter ended Mar 31, 2024: revenue n/a, net income −$31.0M, EPS −$0.56
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$26.8M, EPS −$0.47
- Quarter ended Sep 30, 2023: revenue n/a, net income −$21.5M, EPS −$0.48
- Quarter ended Jun 30, 2023: revenue n/a, net income −$20.1M, EPS −$0.49
- Quarter ended Mar 31, 2023: revenue n/a, net income −$28.3M, EPS −$0.70
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$26.2M, EPS −$0.65
- Quarter ended Sep 30, 2022: revenue n/a, net income −$22.7M, EPS −$0.57
- Quarter ended Jun 30, 2022: revenue n/a, net income −$32.9M, EPS −$0.82
- Quarter ended Mar 31, 2022: revenue n/a, net income −$23.0M, EPS −$0.58
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$21.6M, EPS −$0.54
- Quarter ended Sep 30, 2021: revenue n/a, net income −$17.7M, EPS −$0.45
OLMA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$147M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$104M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$83.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$82.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$50.7M, share buybacks n/a
OLMA balance sheet
- Jun 30, 2026: cash $48.6M, total assets $487M, total liabilities $56.0M, shareholders' equity $431M
- Mar 31, 2026: cash $52.5M, total assets $531M, total liabilities $50.2M, shareholders' equity $480M
- Dec 31, 2025: cash $48.3M, total assets $533M, total liabilities $54.9M, shareholders' equity $479M
- Sep 30, 2025: cash $35.3M, total assets $352M, total liabilities $45.0M, shareholders' equity $307M
- Jun 30, 2025: cash $52.5M, total assets $382M, total liabilities $36.8M, shareholders' equity $345M
- Mar 31, 2025: cash $50.6M, total assets $410M, total liabilities $26.2M, shareholders' equity $383M
- Dec 31, 2024: cash $139M, total assets $451M, total liabilities $42.0M, shareholders' equity $409M
- Sep 30, 2024: cash $35.9M, total assets $230M, total liabilities $31.3M, shareholders' equity $199M
Is OLMA profitable?
No. OLEMA PHARMACEUTICALS INC lost $205M over the last four quarters.
What is OLMA's EPS?
Diluted earnings per share over the last four quarters were −$2.13; −$0.61 in the latest quarter.